Zhi Tong Cai Jing·2025-09-11 03:18Core Viewpoint - Rongchang Biopharma (09995) has seen a significant stock movement following the acceptance of its innovative drug, Taitasip, for the treatment of Sjögren's syndrome by the National Medical Products Administration (NMPA) in China, marking a potential breakthrough in the field [1] Company Developments - Rongchang Biopharma's stock opened down over 7% but later rose by 5.13%, reaching HKD 106.6 with a trading volume of HKD 805 million [1] - The company announced that Taitasip, a dual-target fusion protein drug, is the first of its kind globally to submit a marketing application for Sjögren's syndrome [1] - Taitasip has received Fast Track designation from the FDA in the United States and has been approved for Phase III clinical trials for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG) in China [1] Licensing Agreements - Rongchang Biopharma has entered into a licensing agreement with Vor Bio, granting Vor Bio exclusive rights to develop and commercialize Taitasip globally, excluding Greater China [1]